Estrogen potentiates prostaglandin E₂-stimulated duodenal mucosal HCO₃⁻ secretion in mice

Am J Physiol Endocrinol Metab. 2012 Jul 1;303(1):E111-21. doi: 10.1152/ajpendo.00575.2011. Epub 2012 Apr 24.

Abstract

The cause of lower prevalence of duodenal ulcer in young women compared with men is largely unknown. We recently found that sex difference in duodenal mucosal HCO₃⁻ secretion existed in humans and mice, but the mechanisms are not clear. Prostaglandin E₂ (PGE₂) is an important endogenous mediator that plays an important role in the regulation of duodenal HCO₃⁻ secretion. Therefore, in the present study, we investigated the effect of estrogen on PGE₂-stimulated duodenal HCO₃⁻ secretion and the underlying mechanisms. The results showed that 17β-estradiol at the physiological concentration (1 nM) had no significant effects on duodenal mucosal HCO₃⁻ secretion or short-circuit current (I(sc)) in mice. However, the pretreatment of 17β-estradiol (1 nM) markedly potentiated PGE₂-stimulated duodenal HCO₃⁻ secretion and I(sc) (P < 0.01 and P < 0.05). Global estrogen receptor (ER) antagonist ICI-182,780 and ERα-specific antagonist MPP, but not the ERβ-specific antagonist PHTPP, abolished estrogen-potentiated PGE₂-stimulated duodenal HCO₃⁻ secretion and I(sc). 17β-Estradiol and PGE₂ additively increased phosphatidylinositol 3-kinase (PI3K) activity and Akt phosphorylation. Wortmannin, a specific PI3K inhibitor, inhibited estrogen-potentiated PGE₂-stimulated duodenal HCO₃⁻ secretion and I(sc). In conclusion, estrogen at the physiological concentration potentiates PGE₂-stimulated duodenal mucosal HCO₃⁻ secretion through the activation of ERα and the PI3K-dependent mechanism, which may contribute to the sex difference in duodenal mucosal HCO₃⁻ secretion and the lower prevalence of duodenal ulcer in young women.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bicarbonates / metabolism*
  • Dinoprostone / agonists
  • Dinoprostone / metabolism*
  • Duodenum / drug effects
  • Duodenum / metabolism*
  • Enzyme Inhibitors / pharmacology
  • Estradiol / chemistry
  • Estradiol / metabolism*
  • Estrogen Antagonists / pharmacology
  • Estrogen Receptor alpha / antagonists & inhibitors
  • Estrogen Receptor alpha / metabolism
  • Estrous Cycle
  • Female
  • In Vitro Techniques
  • Intestinal Mucosa / drug effects
  • Intestinal Mucosa / metabolism*
  • Male
  • Mice
  • Phosphatidylinositol 3-Kinase / metabolism
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphorylation
  • Protein Processing, Post-Translational
  • Proto-Oncogene Proteins c-akt / metabolism
  • Secretory Pathway* / drug effects
  • Sex Characteristics
  • Signal Transduction / drug effects

Substances

  • Bicarbonates
  • Enzyme Inhibitors
  • Estrogen Antagonists
  • Estrogen Receptor alpha
  • Phosphoinositide-3 Kinase Inhibitors
  • Estradiol
  • Phosphatidylinositol 3-Kinase
  • Proto-Oncogene Proteins c-akt
  • Dinoprostone